precision medicine Archives

Biotech professionals collaborate in a modern laboratory with molecular models, digital research displays and blue and green upward arrows symbolizing growth.

Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB $MRK $MRNA $NVAX $SNY $XBI )

by John F. Heerdink, Jr. October 10, 2026 460Views 0Likes

Clinical progress, a proposed U.S. research initiative and vaccine licensing economics strengthen the bull case. Biotechnology investors are finding fresh reasons to look beyond the pandemic trade. Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX) and Merck (NYSE: MRK) rallied on October 9 as…

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. October 8, 2026 362Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Alt Text: Illustration of the Nobel Prize in Medicine lighting a new bull market for brain science, featuring a glowing brain, neural connections, a rising stock-market chart and a charging digital bull above a city skyline as researchers look on.

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

by John F. Heerdink, Jr. October 5, 2026 332Views 0Likes

The 2026 Nobel Prize in Physiology or Medicine has put optogenetics, the science of using light to control precisely selected nerve cells, squarely in the global spotlight. For many, the award is more than a ceremonial victory lap for academic neuroscience:…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 427Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Digital Nasdaq billboard in Times Square highlighting Eupraxia Pharmaceuticals (NASDAQ: EPRX), its Nasdaq Global Select Market upgrade, and the upcoming eosinophilic esophagitis clinical-data catalyst.

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. September 8, 2026 299Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has moved up to the Nasdaq Global Select Market just as its lead clinical program approaches a pivotal Phase 2b interim data event. For many, the timing is rather tidy: the company is pairing greater market…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 299Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Comic-book-style illustration of a confident superhero in a teal suit with an “R” molecular symbol flying above a modern city skyline. Large headline text reads “Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention,” while surrounding signs reference Revolution Medicines, RVMD stock, innovation, cancer breakthrough and oncology leadership.

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

by John F. Heerdink, Jr. September 1, 2026 289Views 0Likes

Revolution Medicines, Inc. (NASDAQ: RVMD) seems to have crossed the line that separates a compelling biotech hypothesis from a commercial oncology story: the U.S. Food and Drug Administration approved its first medicine, RASONQUE (daraxonrasib), for certain adults with metastatic pancreatic adenocarcinoma. The approval…

Investor infographic illustrating Eli Lilly and Company (NYSE: LLY) investing up to $2.875 billion to acquire Merida Biosciences, linking Lilly’s headquarters and cash investment to Merida’s antibody-engineering candidates, precision immunology research, and projected future revenue growth.

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. September 1, 2026 264Views 0Likes

Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…

Promotional graphic for Tribe Public’s Eupraxia Pharmaceuticals webinar, “Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story,” featuring CEO James Helliwell, MD; EoE inflammation imagery, precision-healing graphics and event details for Friday, August 21, 2026.

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. August 21, 2026 389Views 0Likes

Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21 Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

by John F. Heerdink, Jr. August 19, 2026 389Views 0Likes

The biotechnology market has a habit of demanding patience right up until it abruptly decides to reward it. Moderna, Inc. (NASDAQ: MRNA) recently reminded investors of that rule as enthusiasm around its personalized melanoma-vaccine program with Merck & Co., Inc. (NYSE: MRK)…

Tag: precision medicine

Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB $MRK $MRNA $NVAX $SNY $XBI )

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

Your Guide To Staying Informed In The Markets